CRX-527 - Cell culture tested - TLR4 Agonist

Synthetic lipid A analog - TLR4 agonist

CRX-527 is a synthetic lipid A mimic belonging to the aminoakyl glucoaminide 4-phosphate (AGP) family [1]. Similar to lipid A, the active component of lipopolysaccharide (LPS), CRX-527 activates Toll-like receptor 4 (TLR4).  Subsequently, it initiates MyD88- and TRIF-dependent pro-inflammatory signaling cascades. Importantly, CRX-527 does not require the TLR4 co-receptor CD14 for activation of either signaling pathway [2]. CRX-527, along with other AGPs, is less toxic than LPS and importantly retains its immunostimulatory properties. Therefore, AGPs have great potential as future vaccine adjuvants as well as stand‑alone immunostimulants [3].

CRX-527 is composed of a monosaccharide unit glycosidically linked to an L-serine-based aglycon unit. It is a hexa -acylated molecule consisting of three "primary" myristic (C14) and three decanoic (C10) acyl chains. Interestingly, most likely due to its structure CRX-527 does not activate a typical Limulus amebocyte lysate (LAL) assay commonly used for measuring endotoxin levels.

Key highlights of CRX-527:

• Highly specific and potent TLR4 agonist
• Displays significantly less toxicity when compared to LPS
• Doesn't require the co-receptor CD14 for TLR4 activation and signaling

InvivoGen's CRX-527 is of the highest quality, guaranteed free of bacterial contamination, and has been functionally validated on HEK-Blue™ hTLR4 cells.

Learn more about TLR4 and its co-receptors

Learn more about different Lipid A structures

References:

1. Stover, A.G. et al. 2003.Structure-activity relationship of synthetic Toll-like receptor 4 agonists. J. Biol. Chem. 279:4440-4449.
2. Legat, A.et al. 2010.CD14-independent responses induced by a synthetic lipid A mimetic. Eur. J. Immunol. 40:792-802.
3. Tan, Z.Y. et al. 2013. Synthetic TLR4 agonists as a potential immunotherapy for melioidosis. Open J Immunol. 3: 1-9.